EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Author's Reply: “Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?”

Paula Sousa, Fernando Magro

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2023.12.006 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Paula Sousa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Viseu-Tondela Hospital Centre, Viseu, Portugal. Hauptthemen laut MEDLINE: Immunologic Factors, Crohn Disease. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunologic FactorsCrohn DiseaseHumansInfliximabCombined Modality TherapyDrug Therapy, Combination

Substanzen

InfliximabImmunologic Factors

Autor:innen und Institutionen

  • Department of Gastroenterology, Viseu-Tondela Hospital Centre, Viseu, Portugal.
  • Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal; CINTESIS@RISE,…

Zitieren

APA

Sousa, P., & Magro, F. (2024). Author's Reply: “Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?”. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.12.006

Vancouver

Sousa P, Magro F. Author's Reply: “Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?”. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.12.006

BibTeX
@article{Sousa2024,
  author = {Sousa, Paula and Magro, Fernando},
  title = {Author's Reply: “Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?”},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2023.12.006}
}
Kostenlos starten →